The role of a potential biomarker in patients with migraine: review and new insights

References

• Victor TW, Hu X, Campbell JC, et al. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30(9):1065–1072.
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Nichols E, Steiner TJ, et al. Global, the regional and national burden of migraine and tension-type headache, 1990-2016 a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2018;17(11):954–976.
   PubMed Web of Science ®Google Scholar
• Ramage-Morin PL, Gilmour H. Prevalence of migraine in the Canadian household population. Health Rep. 2014;25(6):10–16.
   Web of Science ®Google Scholar
• Stokes M, Becker W, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS). Headache. 2011;51(7):1058–1077.
   PubMed Web of Science ®Google Scholar
• International Headache Society. The international classification of headache disorders: 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Tinsley A, Rothrock JF. What are we missing in the diagnostic criteria for migraine? Curr Pain Headache Rep. 2018;22(12):84.
   PubMed Web of Science ®Google Scholar
• Recober A. Pathophysiology of Migraine. Continuum (Minneap Minn). 2021;27(3):586596.
   Google Scholar
• Gormley P, Antilla V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet. 2016;48(8):856–866.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ. Preventive therapy of migraine. Continuum (Minneap Minn). 2018;24(4):1052–1065.
   PubMedGoogle Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine a randomized clinical trial. JAMA. 2018;319(19):5–14.
   Web of Science ®Google Scholar
• Schwedt TJ. Chronic migraine. BMJ. 2014;348(mar24 5):g1416–g1416.
   PubMedGoogle Scholar
• Benoliel R, Svensson P, Evers S, et al. The IASP classification of chronic pain for ICD-11: chronic secondary headache or orofacial pain. Pain. 2019;160(1):60–68.
   PubMed Web of Science ®Google Scholar
• Giacomozzi AR, Vindas AP, De Silva AA, et al. Latin American consensus on guidelines for chronic migraine treatment. Arq Neuropsiquiatr. 2013;71(7):478–486.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol. 2009;8(6):560–568.
   PubMed Web of Science ®Google Scholar
• Valfre W, Innocenzo R, Bergui M, et al. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache. 2008;48(1):109–117.
   PubMed Web of Science ®Google Scholar
• Dressler T, Caratozzolo F, Guldolf K, et al. Understanding the nature of psychiatric comorbidity in migraine: a systematic review focused on interactions and treatment implication. J Headache Pain. 2019;20(1):51.
   PubMedGoogle Scholar
• Ferreira KS, Teixeira CT, Cafaro C, et al. Chronic migraine patients show cognitive impairment in an extended neuropsychological assessment. Arq Neuropsiquiatr. 2018;76(9):582–587.
   PubMed Web of Science ®Google Scholar
• Velly AM, Mohit S, Schipper HM, et al. Biomarkers in Epidemiologic Research: definition, Classification, and Implication. In: Goulet JP, Velly A, editors. Orofacial Pain Biomarkers. Berlin: Springer, Heidelberg; 2017. 1- 155. DOI:10.1007/978-3-662-53994-1_10
   Google Scholar
• Lipton RB. Inflaming the need for migraine biomarkers. Neurology. 2014;83(24):2198–2199.
   Web of Science ®Google Scholar
• Van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: a systematic review and meta-analysis. Cephalalgia. 2017;37(1):49–63.
   PubMed Web of Science ®Google Scholar
• Frederiksen SD, Bekker-Nielsen Dunbar M, Snoer AH, et al. Serotonin and neuropeptides in blood from episodic and chronic migraine and cluster headache patients in case-control and case-crossover settings: a systematic review and meta-analysis. Headache. 2020;60(6):1132–1164.
   PubMed Web of Science ®Google Scholar
• Neri M, Frustaci A, Milic M, et al. A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. Cephalalgia. 2015;35(10):931–937.
   PubMed Web of Science ®Google Scholar
• Lippi G, Mattiuzzi C, Cervellin G. C-reactive protein and migraine. Facts or speculations? Clin Chem Lab Med. 2014;52(9):1265–1272.
   PubMed Web of Science ®Google Scholar
• Durham P, Papapetropoulos S. Biomarkers associated with migraine and their potential role in migraine management. Headache. 2013;53(8):1262–1277.
   PubMed Web of Science ®Google Scholar
• Ferroni P, Barbanti P, Spila A, et al. Circulating biomarkers in migraine. new opportunities for precision medicine. Curr Med Chem. 2019;26(34):6191–6206.
   PubMed Web of Science ®Google Scholar
• Ferroni P, Barbanti P. Biomarkers in migraine headache: prognostic and therapeutic implications. Curr Med Chem. 2019;26(34):6188–6190.
   PubMed Web of Science ®Google Scholar
• Tietjen GE, Khubchamdani J. Vascular biomarkers in migraine. Cephalalgia. 2015;35(2):95–117.
   PubMed Web of Science ®Google Scholar
• Peterlin BL, Sacco S, Bernecker C, et al. Adipokines and Migraine: a systematic review. Headache. 2016;56(4):622–644.
   PubMed Web of Science ®Google Scholar
• Lee MJ, Lee SY, Cho S, et al. Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain. 2018;19(1):53.
   PubMedGoogle Scholar
• Jang MU, Park JW, Kho HS, et al. Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients. Oral Dis. 2011;17(2):187–193.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–1196.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Ramón C, Martínez-Camblor P, et al. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;156(5):820–824.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Martínez-Camblor P, Ramón C, et al. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine. Headache. 2014;54(6):987–995.
   PubMed Web of Science ®Google Scholar
• Dominguez C, Vieites-Prado A, Perez-Mato M, et al. CGRP and PTX3 as predictors of efficacy of onabotulinumtoxin type A in chronic migraine patients. Headache. 2018;58(1):7887.
   Web of Science ®Google Scholar
• Cady R, Turner I, Dexter K, et al. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventive treatment with onabotulinumtoxin A in chronic migraine. Headache. 2014;54(2):269–277.
   PubMed Web of Science ®Google Scholar
• Nam JH, Lee HS, Kim J, et al. Salivary glutamate is elevated in individuals with chronic migraine. Cephalalgia. 2018;38(8):1485–1492.
   PubMed Web of Science ®Google Scholar
• Campos F, Sobrinho P, Perez-Mato M, et al. Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients. Cephalalgia. 2013;33(14):1148–1154.
   PubMed Web of Science ®Google Scholar
• Ferrari A, Spaccapelo L, Pinetti D, et al. Effective prophylactic treatments of migraine lower plasma glutamate levels. Cephalalgia. 2009;29(4):423–429.
   PubMed Web of Science ®Google Scholar
• Martami F, Razeghi J, Togha M, et al. The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci. 2018;39(10):1741–1749.
   PubMed Web of Science ®Google Scholar
• Yazar HO, Yazar T, Aygun A, et al. Evaluation of simple inflammatory blood parameters in patients with migraine. Ir J Med Sci. 2019;189(2):667–683.
   Web of Science ®Google Scholar
• Dini E, Mazzuchi S, De Luca C, et al. Plasma Levels of Oxidative Stress Markers, before and after BoNT/A Treatment, in Chronic Migraine. Toxins (Basel). 2019;11(10):608. pii: E608.
   PubMed Web of Science ®Google Scholar
• Van der Schueren BJ, Verbrugge FH, Verbesselt R, et al. No arguments for increased endothelial nitric oxide synthase activity in migraine based on peripheral biomarkers. Cephalalgia. 2010;30(11):1354–1365.
   PubMed Web of Science ®Google Scholar
• Bougea A, Spantideas N, Galanis P, et al. Salivary inflammatory markers in tension-type headache and migraine: the SalHead cohort Study. Neurol Sci. 2019;41(4):877–884.
   PubMed Web of Science ®Google Scholar
• Grazzi L, D`amico D, Raggi A, et al. Mindfulness and pharmacological prophylaxis have comparable effect on biomarkers of inflammation and clinical indexes in chronic migraine with medication overuse: results at 12 months after withdrawal. Neurol Sci. 2017;38(S1):173–175.
   PubMedGoogle Scholar
• Yuasa N, Nagata E, Fujii N, et al. Serum apolipoprotein E may be a novel biomarker of migraine. PlosOne. 2018;13(1):e0190620.
   PubMed Web of Science ®Google Scholar
• Pereda SP, Suarez MT, Ocejo-Vinyals G, et al. Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine. Patients in Real Clinical Practice. 2020;47:7125–7138.
   Google Scholar
• Peterlin BL, Alexander G, Tabby D, et al. Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology. 2008;70(20):1905–1911.
   PubMed Web of Science ®Google Scholar
• Duarte H, Teixeira AL, Rocha NP, et al. Increased serum levels of adiponectin in migraine. J Neurol Sci. 2014;342(1–2):186–188.
   PubMed Web of Science ®Google Scholar
• Dearborn JL, Schneider AL, Gottesman RF, et al. Adiponectin and leptin levels in migraineurs in the atherosclerosis risk in communities study. Neurology. 2014;83(24):2211–2218.
   PubMed Web of Science ®Google Scholar
• Guldiken B, Guldiken S, Demir M, et al. Low leptin levels in migraine: a case control study. Headache. 2008;48(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Ligong Z, Jinjin Q, Chunfu C, et al. Effect of obesity and leptin level on migraineurs. Med Sci Monit. 2015;21:3270–3274.
   PubMed Web of Science ®Google Scholar
• Bugdayci G, Yildiz S, Altunrende B, et al. Salivary alpha amylase in migraine patients. Auton Neurosci. 2010;155(1–2):121–124.
   PubMed Web of Science ®Google Scholar
• Ciregia F, Giacomelli C, Giusti L, et al. Putative salivary biomarkers useful to differentiate patients with fibromyalgia. J Proteomics. 2019;190(6):44–54.
   PubMedGoogle Scholar
• Koverech A, Cicione C, Lionetto L, et al. Migraine and cluster headache show impaired neurosteroids patters. J Headache Pain. 2019;20(1):61.
   PubMedGoogle Scholar
• Rainero I, Vacca A, Govone F, et al. Migraine: genetic variants and clinical phenotypes. Curr Med Chem. 2019;26(34):6207–6221.
   PubMed Web of Science ®Google Scholar
• Kondratieva N, Azimova J, Skorobogatykh K, et al. Biomarkers of migraine: part 1 - Genetic markers. J Neurol Sci. 2016;369(63):63–76.
   PubMedGoogle Scholar
• Cheng CY, Chen SP, Liao YC, et al. Elevated circulating endothelial-specific microRNAs in migraine patients: a pilot study. Cephalalgia. 2018;38(9):1585–1591.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Cione E, Peltrone F, et al. Hsa-miR-34a-5p and hsa-miR-375 as biomarkers for monitoring the effects of drug treatment for migraine pain in children and adolescents: a pilot study. J Clin Med. 2019;8(7):928.
   Web of Science ®Google Scholar
• Greco R, De Icco R, Demartini C, et al. Plasma levels of CGRP and expression. Of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain. 2020;21(1):122.
   PubMed Web of Science ®Google Scholar
• Davis K, Aghaeepour N, Ahn AH, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020;16(7):381–400.
   PubMed Web of Science ®Google Scholar
• Tardiolo G, Bramanti P, Mazzon E. Migraine: experimental models and novel therapeutic approaches. Int. J. Mol Sci. 2019;20(12):2932.
   Web of Science ®Google Scholar
• Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15(2):361–370.
   PubMed Web of Science ®Google Scholar
• Christensen CE, Younis S, Deen M, et al. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain. 2018;19(1):105.
   PubMedGoogle Scholar
• Patel MK, Kaye AD, Urman RD. Tanezumab: therapy targeting nerve growth factor in pain pathogenesis. J Anaesthesiol Clin Pharmacol. 2018;34(1):111–116.
   PubMed Web of Science ®Google Scholar
• Markman JD, Bolash RB, Mc Alindon TE, et al. Tanezumab for chronic low back pain: a randomized, double-blind, placebo and active-controlled, phase 3 study of efficacy and safety. Pain. 2020;161(9):2068–2078.
   Web of Science ®Google Scholar
• Rustichelli C, Castro FL, Baraldi C, et al. Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review. Expert Opin Investig Drugs. 2020;29(11):1269–1275.
   PubMed Web of Science ®Google Scholar
• Ashina M, Dolezil D, JoH B, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021;41(1):33–44.
   PubMed Web of Science ®Google Scholar
• Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia. 2019;39(12):1535–1543.
   PubMed Web of Science ®Google Scholar
• Rajda C, Tajti J, Komoroczy R, et al. Amino acids in the saliva of patients with migraine. Headache. 1999;39(9):644–649.
   PubMedGoogle Scholar
• Fischer HP, Eich W, Russell IJ. A possible role for saliva as a diagnostic fluid in patients with chronic pain. Semin Arthritis Rheum. 1998;27(6):348–359.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Wang PJ, Chen CH, et al. Homozygous deletion genotype of angiotensin converting enzyme confers protection against migraine in man. Acta Neurol Taiwan. 2005;14(3):120–125.
   PubMedGoogle Scholar
• Del Zompo M, Cherchi A, Palmas MA, et al. Association between dopamine receptor genes and migraine without aura in a Sardinian sample. Neurology. 1998;51(3):781–786.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Cione E, Caroleo MC, et al. microRNAs to monitor pain-migraine and drug treatment. MicroRNA. 2017;6(3):152–156.
   PubMedGoogle Scholar
• Gallelli L, Siniscalchi A, Carotenuto M, et al. microRNAs-based predictor factor in patients with migraine-ischemic stroke. MicroRNA. 2017;6(1):17–21.
   PubMedGoogle Scholar
• Andersen HH, Duroux M, Gazerani P. Serum MicroRNA signatures in migraineurs during attacks and in pain-free periods. Mol Neurobiol. 2016;53(3):1494–1500.
   PubMed Web of Science ®Google Scholar
• Tafuri E, Santovito D, Nardis V, et al. MicroRNA profiling in migraine without aura: pilot study. Ann Med. 2015;47(6):468–473.
   PubMed Web of Science ®Google Scholar
• Frederiksen SD. Promote biomarker discovery by identifying homogenous primary headache subgroups. Headache. 2019;59(5):797–801.
   PubMed Web of Science ®Google Scholar
• Rubino E, Vacca A, Govone F, et al. Investigating the role of adipokines in chronic migraine. Cephalalgia. 2017;37(11):1067–1073.
   PubMed Web of Science ®Google Scholar
• Bernecker C, Pailer S, Kieslinger P, et al. Increased matrix metalloproteinase activity is associated with migraine and migraine-related metabolic dysfunctions. Eur J Neurol. 2011;18(4):571–576.
   PubMed Web of Science ®Google Scholar
• Bernecker C, Ragginer C, Fauler G, et al. Oxidative stress is associated with migraine and migraine-related metabolic risk in females. Eur J Neurol. 2011;18(10):1233–1239.
   PubMed Web of Science ®Google Scholar